Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection

• Published in: Vaccine 2021-07, Vol.39 (30), p.4135-4143
• Main Authors: Luo, Jin, Huo, Chunling, Qin, Huan, Hu, Junhong, Lei, Lei, Pan, Zishu
• Format: Article
• Language: English
• Subjects: Antibodies; Baculovirus; Children; Chimeras; Chimeric vaccine; Cloning; Coxsackievirus A16; Coxsackieviruses; Cross-protection; Cytokines; Deactivation; Enterovirus 71; Enteroviruses; Enzymes; Epitopes; Genomes; Hand-foot-and-mouth disease; Immune response; Immune response (cell-mediated); Immunization; Immunoglobulin G; Infections; Infectious diseases; Interleukin 10; Interleukin 4; Lymphocytes T; Mutagenesis; Neonates; Neutralizing; Plasmids; Polyhedrin; Proteins; Splenocytes; Vaccination; Vaccines; Virus-like particle; Virus-like particles; Viruses; VP1 protein; VP3 protein
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2021.05.093

•Chimeric EV71-VLPs elicited both EV71- and CA16-specific antibody responses in mice.•Neonatal mice born to immunized dams conferred protection against EV71 and partial protection against CA16 infection.•Vaccination of chimeric EV71-VLPs elicited a balanced Th1/Th2 cytokine response. Hand-foot-and-mouth disease (HFMD) is an infectious disease of infants and young children frequently caused by the enterovirus A species, mainly enterovirus 71 (EV71) and coxsackievirus A16 (CA16). In this study, we prepared the EV71 virus-like particle (EV71-VLP) and its chimeras using recombinant baculovirus (Bac-P1-3CD) co-expressing EV71 P1 (under polyhedrin promoter) and 3CD (under CMV-IE promoter) proteins in Sf9 cells. EV71-VLP chimera ChiEV71(1E)-VLP or ChiEV71(4E)-VLP displayed single CA16 PEP71 epitope in VP1 or four conserved CA16 neutralizing epitopes (PEP71 in VP1, aa136-150 in VP2, aa176-190 in VP3 and aa48-62 in VP4) by substitution of the corresponding regions of EV71 structure proteins, respectively. In mice, EV71-VLP and its chimeras elicited similar EV71-specific IgG and neutralizing antibody (NAb) titers compared to inactivated EV71. Expectedly, vaccination of ChiEV71(1E)-VLP or ChiEV71(4E)-VLP resulted in significantly increased CA16-specific IgG and NAb production and improved cross-protection against CA16 infection compared to EV71-VLP. Interestingly, the VLPs induced potent cellular immune responses and significantly decreased Th2 type (IL-4 and IL-10) cytokines secretion in the splenocytes of immunized mice compared to inactivated EV71 or inactivated CA16. Neonatal mice born to dams immunized with the chimeric VLPs or neonatal mice passively transferred with sera of immunized mice were completely protected from lethal EV71 challenge and partially protected from lethal CA16 infection. Our study provides a novel bivalent or multivalent vaccine strategy to prevent EV71 and related-enterovirus infections.